The fabulous story of glyphozines.

Authors

DOI:

https://doi.org/10.56867/

Keywords:

Diabetes mellitus, History, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Renal Insufficiency, Chronic.

Abstract

Introduction: The surprising history of gliflozins begins with the phlorizin-induced renal diabetes model and culminates with synthesizing the C glycosides derived from phloridzin: gliflozins. These drugs, specifically SGLT2 inhibitors, constitute a new class of oral antidiabetics with unsuspected beneficial effects on cardiovascular and
renal levels.

Objective of the review: The aim of the present historical narrative review of the events related to developing
glyphozins from phlorizin.
Essential points of the review:
• Phloridzin or phlorizin, a natural O-glucoside, was discovered in 1835 by two Belgian chemists: Laurent Guillaume de Koninck (1809-1887) and Jean Servais Stas (1813-1891).
• Joseph von Mering described in 1883 the glucosuric effects of phlorizin, first in dogs, then in humans,
which will lead to a model of nephrogenic diabetes.
• In the 1950s, phlorizin was observed to block glucose transport in different epithelia, including the kidney
and intestine.
• Today, phlorizin is known to be a nonspecific antagonist of glucose (GLUT) receptors. We also owe a lot
to patients with congenital glycosuria, in whom inactivating mutations of GLUT receptors were identified.

Conclusion: The fabulous fate of gliflozins illustrates the relevance of the history of medicine and translational
research that allowed significant therapeutic advances for many diabetic, renal, and cardiac patients.

Published

2023-08-15

Issue

Section

Narrative Review

How to Cite

The fabulous story of glyphozines. (2023). Revista De La Sociedad Ecuatoriana De Nefrología, Diálisis Y Trasplante, 11(2), 91-97. https://doi.org/10.56867/

Similar Articles

1-10 of 61

You may also start an advanced similarity search for this article.